摘要 |
A novel crystalline Form of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3- ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(pentanoyl{2''-(tetrazol-5- ylate)biphenyl-4'-ylmethyl}amino)butyrate] hydrate, process for its preparation, pharmaceutical composition comprising the new form, and use of it for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition is disclosed. The novel form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. |
申请人 |
CRYSTAL PHARMATECH INC.;CRYSTAL PHARMATECH CO., LTD.;SUZHOU PENGXU PHARMATECH CO., LTD. |
发明人 |
CHEN, MINHUA;ZHANG, YANFENG;YANG, CHAOHUI;ZHANG, XIAOYU;LI, JIAOYANG;WANG, PENG;LI, PIXU |